Extracellular chaperones modulate the effects of Alzheimer’s patient cerebrospinal fluid on Aβ1-42 toxicity and uptake
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease is characterised by the inappropriate death of brain cells and accumulation of the Abeta peptide in the brain. Thus, it is possible that there are fundamental differences between Alzheimer's disease patients and healthy individuals in their abilities to clear Abeta from brain fluid and to protect neurons from Abeta toxicity. In the present study, we examined (1) the cytotoxicity of Alzheimer's disease cerebrospinal fluid (CSF) compared to control CSF, (2) the ability of Alzheimer's disease and control CSF to protect cells from Abeta toxicity and to promote cell-mediated clearance of Abeta and lastly (3) the effects of extracellular chaperones, normally found in CSF, on these processes. We show that the Alzheimer's disease CSF samples tested were more toxic to cultured neuroblastoma cells than normal CSF. In addition, the Alzheimer's disease CSF samples tested were less able to protect cells from Abeta-induced toxicity and less efficient at promoting macrophage-like cell uptake when compared to normal CSF. The addition of physiologically relevant concentrations of the extracellular chaperones, clusterin, haptoglobin and alpha(2)-macroglobulin into CSF protected neuroblastoma cells from Alphabeta(1-42) toxicity and promoted Alphabeta(1-42) uptake in macrophage-like cells. These results suggest that extracellular chaperones are an important element of a system of extracellular protein folding quality control that protects against Abeta toxicity and accumulation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pathways towards and Away from Alzheimer’s Disease
Mattson, M. P. (2004) · Nature · doi:10.1038/nature02621 · Cited by 3,052 · cited 4×
“Aβ aggregates, such as mature fibrils (Mattson 2004) and soluble oligomers (Klein 2002), are toxic to cells in vitro and are thought to cause pathology in humans Cell Stress and Chaperones (2010) 15:115–121”
BackgroundInfluentialShibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413 · cited 4×
“This is consistent with in vivo studies that show that the rate of clearance of Aβ from the mouse brain is significantly increased by both α2m ( Shibata et al. 2000 ) and clusterin (Bell et al. 2007).”
ResultInfluentialCorrelation Between Elevated Levels of Amyloid β-Peptide in the Brain and Cognitive Decline
Näslund, J. (2000) · JAMA · doi:10.1001/jama.283.12.1571 · Cited by 1,268 · cited 2×
“One or more types of soluble Aβ species are likely to be responsible for the neurotoxicity associated with Alzheimer’s disease, as the pathology is correlated with elevated levels of Aβ in the brain (Naslund et al. 2000) but does not correlate well with the location of insoluble Aβ plaques (Terry et al.”
BackgroundGong, Y., Chang, L., Viola, K. L., Lacor, P. N., Lambert, M. P., Finch, C. E., Krafft, G. A., & Klein, W. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1834302100 · Cited by 1,061 · cited 2×
“…J. Yerbury (*) :M. R. Wilson School of Biological Sciences, University of Wollongong, Northfields Avenue, Wollongong, NSW 2522, Australia e-mail: jyerbury@uow.edu.au J. J. Yerbury Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge, UK (Gong et al. 2003).”
BackgroundBell, R. D., Sagare, A. P., Friedman, A. E., Bedi, G. S., Holtzman, D. M., Deane, R., & Zlokovic, B. V. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600419 · Cited by 670 · cited 4×
“This is consistent with in vivo studies that show that the rate of clearance of Aβ from the mouse brain is significantly increased by both α2m (Shibata et al. 2000) and clusterin (Bell et al. 2007).”
ResultInfluentialWilson, M. R., Yerbury, J. J., & Poon, S. (2007) · Molecular BioSystems · doi:10.1039/b712728f · Cited by 142 · cited 2×
“This is in accordance with the theory that these extracellular chaperones play a role in sequestering and disposing of dangerously hydrophobic proteins or peptides in vivo (Yerbury et al. 2005a,b; Wilson et al. 2008).”
BackgroundResultSelf-citationNilselid, A.-M., Davidsson, P., Nägga, K., Andreasen, N., Fredman, P., & Blennow, K. (2006) · Neurochemistry International · doi:10.1016/j.neuint.2005.12.005 · Cited by 104 · cited 3×
“In contrast, previous studies suggested that the concentration of at least one of the extracellular chaperones, clusterin, is not lower in Alzheimer’s CSF (Lidstrom et al. 2001; Nilselid et al. 2006).”
MethodResultKida, E., Choi-Miura, N.-H., & Wisniewski, K. E. (1995) · Brain Research · doi:10.1016/0006-8993(95)00482-6 · Cited by 79 · cited 1×
“All three of these known extracellular chaperones can be detected colocalised with “plaques” in Alzheimer’s disease (Powers et al. 1981; Strauss et al. 1992; Kida et al. 1995).”
Background
Cited by
Clusterin in Alzheimer’s Disease: Mechanisms, Genetics, and Lessons From Other Pathologies
Foster, E. M., Dangla-Valls, A., Lovestone, S., Ribe, E. M., & Buckley, N. J. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00164 · Cited by 381
“Clusterin’s ability to interact and bind to Aβ appears to alter aggregation and promote Aβ clearance, suggesting a neuroprotective role (DeMattos et al., 2004; Bell et al., 2007; Nuutinen et al., 2007; Yerbury and Wilson, 2010; Cascella et al., 2013; Narayan et al., 2014; Merino-Zamorano et al., 2016; Yeh et al., 2016…”
BackgroundSecondary nucleation and elongation occur at different sites on Alzheimer’s amyloid-β aggregates
Scheidt, T., Łapińska, U., Kumita, J. R., Whiten, D. R., Klenerman, D., Wilson, M. R., Cohen, S. I. A., Linse, S., Vendruscolo, M., Dobson, C. M., et al. (2019) · Science Advances · doi:10.1126/sciadv.aau3112 · Cited by 164
Self-citationAlzheimer’s as a Systems-Level Disease Involving the Interplay of Multiple Cellular Networks
Castrillo, J. I., & Oliver, S. G. (2016) · Methods in Molecular Biology · doi:10.1007/978-1-4939-2627-5_1 · Cited by 44
D. Bruce, K., Tang, M., Reigan, P., & H. Eckel, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218338 · Cited by 36
“Although there have been reports that CLU facilitates [39] and impedes Aβ clearance [40], it is argued that the outcome of the interaction relates to the CLU: Aβ ratio, and that either factor in excess determines a neuroprotective or neurotoxic outcome [41,42].”
BackgroundPhosphorylated Tau 181 Serum Levels Predict Alzheimer’s Disease in the Preclinical Stage
Qin, W., Li, F., Jia, L., Wang, Q., Li, Y., Wei, Y., Li, Y., Jin, H., & Jia, J. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.900773 · Cited by 23
“In previous studies, haptoglobin suppressed amyloid fibril formation and prevented Aβ toxicity (Yerbury et al., 2009; Yerbury and Wilson, 2010).”
Background
Metadata
- Authors
- Yerbury, J. J., & Wilson, M. R.
- Venue
- Cell Stress and Chaperones
- Publisher
- Elsevier BV
- Published
- 2010-01
- Volume
- 15
- Issue
- 1
- Pages
- 115-121
- ISSN
- 1355-8145 (ISSN-L)
- OpenAlex
- W2082288818
- Cited by
- 64
- References
- 8
- FWCI
- 2.56
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Extracellular chaperones modulate the effects of Alzheimer’s patient cerebrospinal fluid on Aβ1-42 toxicity and uptake. https://app.cochat.ai/papers/10.1007/s12192-009-0122-0
- The paper
- Yerbury, J. J., & Wilson, M. R. (2010). Extracellular chaperones modulate the effects of Alzheimer’s patient cerebrospinal fluid on Aβ1-42 toxicity and uptake. Cell Stress and Chaperones. https://doi.org/10.1007/s12192-009-0122-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.